First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II

被引：0
|
作者：
Delord, Jean-Pierre [1 ]
Bennouna, Jaafar [2 ]
Dieras, Veronique [3 ]
Campone, Mario [2 ]
Lefresne, Florence [4 ]
Aslanis, Vassili [5 ]
Douillard, Jean-Yves [2 ]
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Rene Gauducheau, F-44035 Nantes, France
[3] Inst Curie, Paris, France
[4] Inst Rech Pierre Fabre, Boulogne, France
[5] Inst Rech Pierre Fabre, Castres, France
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3380S / 3380S
页数：1
相关论文
共 50 条
  • [21] FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)
    von Tresckow, B.
    Goebeler, M. E.
    Sayehli, C.
    Gundermann, S.
    Eichenauer, D.
    Aulitzky, W.
    Bacchus, L.
    Igel, S.
    Schwab, M.
    Sasse, S.
    Hauns, B.
    Mais, A.
    Hentsch, B.
    Kohlhof, H.
    Krauss, R.
    Krauss, B.
    Baumgartner, R.
    Vitt, D.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 711 - 711
  • [22] Phase I and pharmacologic study with the novel topoisomerase I/II inhibitor intoplicine administered as a 24-hour infusion
    van Gijn, R
    Huinink, WWT
    Rodenhuis, S
    Vermorken, JB
    van Tellingen, O
    Rosing, H
    van Warmerdam, LJC
    Alakl, MK
    Beijnen, JH
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
  • [23] First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
    Falchook, Gerald S.
    Kurzrock, Razelle
    Amin, Hesham M.
    Xiong, Wenyuan
    Fu, Siqing
    Piha-Paul, Sarina A.
    Janku, Filip
    Eskandari, Ghazaleh
    Catenacci, Daniel V.
    Klevesath, Manfred
    Bruns, Rolf
    Stammberger, Uz
    Johne, Andreas
    Bladt, Friedhelm
    Friese-Hamim, Manja
    Girard, Pascal
    El Bawab, Samer
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1237 - 1246
  • [24] Resveratrol: A novel type of topoisomerase II inhibitor
    Lee, Joyce H.
    Wendorff, Timothy J.
    Berger, James M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (51) : 21011 - 21022
  • [25] Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study
    Maciej Pech
    Andreas Janitzky
    Johann Jacob Wendler
    Christof Strang
    Simon Blaschke
    Oliver Dudeck
    Jens Ricke
    Uwe-Bernd Liehr
    CardioVascular and Interventional Radiology, 2011, 34 : 132 - 138
  • [26] Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study
    Pech, Maciej
    Janitzky, Andreas
    Wendler, Johann Jacob
    Strang, Christof
    Blaschke, Simon
    Dudeck, Oliver
    Ricke, Jens
    Liehr, Uwe-Bernd
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 34 (01) : 132 - 138
  • [27] Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study
    Yuen, Eunice
    Patel, Bharvin
    Smith, Claire
    Posada, Maria
    Bell, Robert
    Ohnmacht, Ute
    Massard, Christophe
    Rodon, Jordi
    Benhadji, Karim
    CANCER RESEARCH, 2016, 76
  • [28] Lung cancer: First-in-man phase I trial with lorlatinib
    Romero D.
    Nature Reviews Clinical Oncology, 2018, 15 (1) : 7 - 7
  • [29] Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
    Wainberg, Zev A.
    de Bono, Johann S.
    Mina, Lida
    Sachdev, Jasgit
    Byers, Lauren Averett
    Chugh, Rashmi
    Zhang, Charlie
    Henshaw, Joshua W.
    Dorr, Andrew
    Glaspy, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [30] PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN - A NOVEL TOPOISOMERASE-I INHIBITOR
    ROWINSKY, EK
    GROCHOW, LB
    HENDRICKS, CB
    ETTINGER, DS
    FORASTIERE, AA
    HUROWITZ, LA
    MCGUIRE, WP
    SARTORIUS, SE
    LUBEJKO, BG
    KAUFMANN, SH
    DONEHOWER, RC
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) : 647 - 656
12345